ArticleBMC complementary medicine and therapies2025
Evaluation of prophylactic and therapeutic activity of camel whey protein and its trypsinized hydrolysate against experimental trichinellosis.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo date, control of trichinellosis has been dependent on the conventional chemotherapeutic agent, albendazole (ALB), with its hitherto unsolved flaws, including a serious adverse profile, minor activity against muscle larva (ML) stages, and resistance development. Camel whey protein (CWP), a unique non-pharmaceutical nutraceutical, has altered the treatment trajectory of a plethora of pathological conditions. The present study aimed to evaluate the prophylactic and therapeutic profile of CWP and its tryptic hydrolysate (TWH) against experimental intestinal and muscular trichinellosis.
methodsCWP and TWH were characterized by free amino acids analysis using the HPLC Pico-Tag method and DPPH free radical scavenging antioxidant assay. 200 µl of five-day oral dosing of CWP and its TWH was prophylactically and therapeutically administered to mice. Parasitological, ultrastructural, biochemical, and histopathological studies were performed for assessment of their anti-trichinella activity. Preclinical data were subjected to analysis of variance and a Tukey post hoc test for pairwise comparisons.
resultsThe free amino acids profile and high DPPH scavenging antioxidant activity of CWP (79.2%) and TWH (82.7%) were determined. Parasitologically, TWH showed the highest prophylactic (84.0%R and 83.8%R) and therapeutic (94.6%R and 93.9%R) activity in mean worm count recovered from intestinal and muscular stages, respectively. Lesser reductions were recorded by CWP, whether prophylactically-treated (73.9%R and 72.1%R) or therapeutically-treated (84.5%R and 83.9%R) against aforementioned stages, respectively. In addition, scanning electron microscopy revealed that the most severe ultrastructural deformities were observed in TWH-treated worms. Biochemically, the prophylactic and therapeutic administration of TWH recorded the highest antioxidant serum level of reduced glutathione (GSH) that curbed the oxidant malondialdehyde (MDA). Histopathologically, TWH ameliorated the intestinal and muscular pathology compared to CWP.
conclusionsTo the best of our knowledge, this is the first study on the prophylactic and therapeutic administration of CWP and TWH against experimental trichinellosis, showing the superiority of TWH in inducing multistage activity and ameliorating the intestinal and muscular pathology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.